Worst performer was TRX:Tissue Regenix which dropped 10% just as I thought it had turned around and was heading in the right direction. This is now down by 38% and losing £684. Seems a long time since I regretted selling my ISA holding for only £71 profit, but now I'm relieved I did.
OPTI:Optibiotix is doing very well dragging itself out of the mire, with a run of really positive news releases. My holdings were up by 11% this week and are now in paper profit of £956 which means in a few weeks it's gone from Nemesis Share to one of my best performers.
CWR:Ceres Power Holdings had a great week, up 17% and now up by 53% on my purchase price. The potential profit has gone up to £964 and I wish I had funds to get some more.
SBTX:SkinBioTherapeutics rose by 18% which is fantastic, but the holding is still down by 21% and losing £222 so a way to go before I'll be really happy.
Share of the Week is IQE:IQE yet again. They had a bad one last week, but were back to normal this week, with my holding increasing in value by 41% on the cost price to go 364% up making £7,120 potential profit on a £1,956 investment. Yippee!
The value over cost gap is back up to the widest it's ever been, despite the cost having risen significantly.
Here's the ISA and share accounts
| Weekly Change | |||
| Portfolio cost | £46,796.25 | +£0 | |
| Portfolio sell value (bid price - commission) | £49,686.97 | (+6.2%) | +£2,462.99 |
| Potential profits | £8,610.17 | +£930.21 | |
| Yr 3 Dividends | £0 | +£0 | |
| Yr 3 Profit from sales | £549.25 | +£0 | |
| Yr 3 Average monthly cash profit | £728.34 | (18.7%) | -£364.17 |
| Total Dividends | £1,179.05 | +£0 | |
| Total Profit from sales | £7,261.74 | +£0 | |
| Average monthly cash profit | £337.57 | (8.7%) | -£3.19 |
| (Sold stocks profit + Dividends - Fees / Months) |
Value up by £2,462 of which most was decresing losses, as OPTI:Optibiotix is still making a loss in the ISA and SBTX:Skinbiotherapeutics is also reduced losses. The increased profits are largely down to IQE:IQE and CWR:Ceres Power, but a dropping AMYT:Amryt Pharma took some of the increased profits away. Projected year 3 average monthly performance is rapidly dropping after the GVC:GVC Holdings sale in week 1 caused the stats to go wild.
Nice spike! Will it hold this time - it doesn't usually...
The SIPP looks like this after week 91
| Weekly Change | |||
| Portfolio cost | £22,828.63 | +£0 | |
| Portfolio sell value (bid price - commission) | £25,190.23 | (10.3%) | +£1,574.55 |
| Potential profits | £3,448.39 | +£1,304.14 | |
| Yr 2 Dividends | £294.96 | +£0 | |
| Yr 2 Profit from sales | £6,575.33 | +£0 | |
| Yr 2 Average monthly cash profit | £756.01 | (39.7%) | -£19.89 |
| Total Dividends | £708.15 | +£0 | |
| Total Profit from sales | £8,925.19 | +£0 | |
| Average monthly cash profit | £453.16 | (23.8%) | -£5.04 |
| (Sold stocks profit + Dividends - Fees / Months) |
Normality returns after last week's massive IQE:IQE sale. OPTI:Optibiotix shook off all its losses and moved into profit, and CAML:Central Asia Metals also had a small tick up to help. TRX:Tissue Regenix let the side down. Average monthly performance after nearly 2 years is twice my target, and the paper value is 10% up too, so this account is deeply satisfying.
I was worried about staying in the black after the sale, but most of the buffer has been restored already.
The trading account looks like this after week 47
| Weekly Change | |||
| Portfolio cost | £486.05 | +£0 | |
| Cash | £79.63 | +£0 | |
| Portfolio sell value (bid price - commission) | £329.99 | (-31.9%) | +£2.78 |
| Potential profits | £0 | +£0 | |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£22.85 | +£0 | |
| Average monthly cash profit | -£1.65 | (-4.1%) | +£0.03 |
| (Sold stocks profit + Dividends - Fees / Months) |
I have started recording year 2 stats now, but seeing as there aren't any, I don't think I'll bother putting them in the table unless something actually happens, which given the track record of this account isn't very likely.
At least it's reasonably consistent...
There are only 4 trading days next week so not sure if much will happen. The main focus is on 5th September when IQE:IQE announce their 6 month results. Last time they announced results the share price tanked for 2 days before bouncing back and heading on its dizzy climb. I'm hoping this will happen again and looking to get some cash available if it does. If it doesn't then I might be tempted with a few more OPTI:Optibiotix. My cunning plan is to sell BDEV:Barratt Developments if it gets a teensy bit closer to break-even, and to sell KIBO:Kibo Mining from my share account if it ticks up the 0.25p I need to make a bit of profit. If that happens early enough next week I can transfer about £2,000 to my ISA before Wednesday and be prepared to strike. I'll still have plenty of KIBO:Kibo Mining in my ISA as I believe it's going to be great, but it's quite high risk whereas IQE:IQE isn't.
The week after next is doubly exciting because AMYT:Amryt Pharma announce 6-month results on 4th September and if there's any sign of early revenue from the recent distribution deal for Lojuxta then things could get quite tasty. This is my 2nd biggest holding after OPTI:Optibiotix at 9% of my portfolio so a small rise can be quite spectacular.
Just got to get next week out of the way first...
No comments:
Post a Comment